The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
1 other identifier
interventional
27
1 country
1
Brief Summary
This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and therefore more hypercoagulable.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable coronary-artery-disease
Started Mar 2007
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
March 24, 2008
CompletedFirst Posted
Study publicly available on registry
March 27, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2008
CompletedResults Posted
Study results publicly available
October 7, 2011
CompletedOctober 7, 2011
September 1, 2011
1.5 years
March 24, 2008
January 6, 2011
September 7, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty
The percentage of platelets that are collagen coated after the administration of clopidogrel.
24 hours after the administration of clopidotrel
Secondary Outcomes (1)
The Percentage of Coated Platelets After Coronary Angiography and/or PCI
6 hrs after procedure
Interventions
Eligibility Criteria
You may qualify if:
- Patients given clopidogrel loading dose before scheduled catheterization or percutaneous intervention
You may not qualify if:
- Acute coronary syndrome
- Unable to tolerate clopidogrel
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VA Medical Center, 1F187
Oklahoma City, Oklahoma, 73104-5076, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Limited to primarily Male VA population.
Results Point of Contact
- Title
- Eliot Schechter, MD
- Organization
- University of Oklahoma Health Sciences Center
Study Officials
- PRINCIPAL INVESTIGATOR
Eliot Schechter, MD
University of Oklahoma
Publication Agreements
- PI is Sponsor Employee
- Yes
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 24, 2008
First Posted
March 27, 2008
Study Start
March 1, 2007
Primary Completion
September 1, 2008
Study Completion
September 1, 2008
Last Updated
October 7, 2011
Results First Posted
October 7, 2011
Record last verified: 2011-09